About health

New information presented at the XXVII Congress of the European Academy of Allergology and Clinical Immunology (EAACI) in Barcelona, Spain, demonstrate AERIUS® (desloratadine) significantly reduces allergy symptoms, including nasal congestion, sneezing, rhinorrhea, nasal pruritus and visual pruritus, in patients with intermittent sensitised rhinitis (IAR) who experience symptoms lasting less than four days per calendar week or less than four-spot weeks per year. The results ar part of the AERIUS Control: Clinical and Evaluative Profile of Treatment (ACCEPT) trials, which were conducted in collaboration with the Global Allergy and Asthma European Network (GA2LEN) and evaluated the safety and efficacy of AERIUS for the intervention of allergic rhinitis (AR), as defined by the updated Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines.

According to the work in patients with IAR, those receiving AERIUS 5 mg for a 15-day treatment menstruum experienced significant reduction in total symptom severity score from baseline versus placebo (-3.01 vs. -2.13; P<0.001). Additionally, patients receiving AERIUS experienced improvement in symptoms as early as the first day of treatment (P=0.001) and lasting for the good 24-hour dosing period across the total study (P<0.001).

“These information show that AERIUS is an effective and well-tolerated first-line treatment for intermittent allergic coryza,” said Jean Bousquet, Department of Pneumonology, University Hospital, Montpellier, France. “The ARIA guidelines distinguish the symptomatic classification of IAR, which is a new agency of thought about and diagnosing allergic reaction symptoms, and now the ACCEPT studies have confirmed which options are effective in treating this new classification of allergic coryza.”

The study also evaluated the personal effects of AERIUS in reducing nasal congestion and other individual symptom scores in patients with IAR. Compared to patients taking placebo, patients with IAR taking AERIUS experienced a significantly greater melioration from baseline in modal nasal over-crowding scores (-0.43 vs. -0.56, respectively; p=0.013). In addition, patients taking AERIUS experienced importantly lower nasal congestion at the goal of the first 24-hour dosing period (P?0.001), versus patients taking placebo. The data too show AERIUS significantly rock-bottom additional IAR symptoms including rhinorrhea, sneezing, eye itch and os nasale itching at the remnant of the 24-hour dosing period on the second day (P?0.035) and over the roost of the 15-day treatment period (P?0.036).

An additional analysis from the ACCEPT trial assessed the ability of patients with IAR to work, go to school or accomplish general daily activities while taking AERIUS, as defined by the Work Productivity Activity Impairment-Allergy Specific (WPAI-AS) questionnaire. Compared to patients with IAR taking placebo, the study plant patients with IAR pickings AERIUS experient a significant reduction in percent overall work-related impairment, compared to patients pickings placebo (24.7 pct vs. 1.6 percent, respectively; P=0.002).

Traditionally, AR has been classified as seasonal or perennial based on the time of exposure and the nature of the allergen (outdoor or indoor). The updated ARIA guidelines classify sensitized rhinitis as intermittent (IAR) or persistent (PER) based on the duration of the toms when accompanied by nasal congestion, in patients 12 days of age and old.5

The most coarse side effects in adults and adolescents with allergic rhinitis and CIU were fatigue, dry mouth and headache.4 In clinical trials in a paediatric population (children aged 6 months through 11 age), the boilersuit incidence of adverse events in children 2 through 11 days of years was similar for the AERIUS syrup and placebo groups.4 In infants and toddlers aged 6 to 23 months, the most haunt adverse events reported in excess of placebo were diarrhea, fever and insomnia.4

Research shows AERIUS provides powerful morning symptom relief for seasonal supersensitised rhinitis patients. In a study of 346 people with moderate-to-severe seasonal allergic rhinitis, patients receiving AERIUS experienced pregnant improvement in morning amount symptom wads (which includes both os nasale and non-nasal symptoms) versus placebo.6 AERIUS offers demonstrated efficaciousness at the end of the dosing interval.4

Schering-Plough markets desloratadine under the brand name names AERIUS, AZOMYR and NEOCLARITYN in Europe, where it is available either as a prescription or non-prescription pharmacy-only medicine, and as prescription CLARINEX® in the United States. AERIUS [AZOMYR] [NEOCLARITYN] builds upon Schering-Plough’s inheritance as a leader in discovery and development.

About Schering-Plough Corporation

Schering-Plough is an innovation-driven, science-centered spherical health concern company. Through its possess biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and ameliorate lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its colleagues around the humans. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

Schering-Plough Disclosure Notice

The information in this press release includes certain “advanced statements” inside the substance of the Private Securities Litigation Reform Act of 1995, including statements relating to potential drop market for AERIUS. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could